1. NCCN Guidelines Insights: Antiemesis, Version 2.2017
- Author
-
Jason J Bergsbaken, Kim Noonan, Hope S. Rugo, Eun-Jeong Kim, David S. Ettinger, Dorothy A. Shead, Dwight D. Kloth, Sally Y. Barbour, Laura Boehnke Michaud, Charles L. Loprinzi, Philip J. Bierman, Ruth Lagman, Georgiana Ellis, John P. Timoney, Susan G. Urba, Michael Berger, Debra Brandt, Bridget Scullion, Victoria Maurer, Dawn E. Dolan, Miranda Hughes, Jonathan Aston, Barbara Todaro, Lee S. Schwartzberg, Cynthia X. Ma, Lisle Nabell, Eric Roeland, Steve Kirkegaard, and Dean Lim
- Subjects
medicine.medical_specialty ,Vomiting ,business.industry ,Neoplasms therapy ,Antineoplastic Agents ,Granisetron ,Clinical Practice ,Benzodiazepines ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Olanzapine ,Neoplasms ,030220 oncology & carcinogenesis ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Antiemetics ,Humans ,Medical physics ,Serotonin Antagonists ,030212 general & internal medicine ,business - Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.
- Published
- 2017